Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial

MA Nauck; G Meininger; D Sheng; L Terranella; PP Stein; Jorma Lahtela

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial

MA Nauck, G Meininger, D Sheng, L Terranella, PP Stein, Jorma Lahtela

Sisätautien vastuualue

Tutkimustuotos: Artikkeli › Scientific › vertaisarvioitu

Alkuperäiskieli	Englanti
Sivut	194-205
Julkaisu	Diabetes Obes Metab
Vuosikerta	9
Numero	2
Tila	Julkaistu - 2007
OKM-julkaisutyyppi	A1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä

YK:n kestävän kehityksen tavoitteet

Tämä tuotos edistää seuraavia kestävän kehityksen tavoitteita:

Siteeraa tätä

@article{99e152a79814412dab426990c33e54a7,

title = "Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial",

author = "MA Nauck and G Meininger and D Sheng and L Terranella and PP Stein and Jorma Lahtela",

year = "2007",

language = "English",

volume = "9",

pages = "194--205",

number = "2",

}

Nauck, MA, Meininger, G, Sheng, D, Terranella, L, Stein, PP & Lahtela, J 2007, 'Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial', Diabetes Obes Metab, Vuosikerta 9, Nro 2, Sivut 194-205.

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. / Nauck, MA; Meininger, G; Sheng, D et al.

julkaisussa: Diabetes Obes Metab, Vuosikerta 9, Nro 2, 2007, s. 194-205.

Tutkimustuotos: Artikkeli › Scientific › vertaisarvioitu

TY - JOUR

T1 - Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial

AU - Nauck, MA

AU - Meininger, G

AU - Sheng, D

AU - Terranella, L

AU - Stein, PP

AU - Lahtela, Jorma

PY - 2007

Y1 - 2007

M3 - Article

VL - 9

SP - 194

EP - 205

IS - 2

ER -